Medicine shortages

terbinafine hydrochloride

Current shortage

The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.

The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.

3 product records on the Australian Register of Therapeutic Goods, listed in full below. The TGA last updated this information on 15 June 2026. Not medical advice.

The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.

This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.

terbinafine hydrochloride is subsidised on the PBS. The active ingredient is on the current Pharmaceutical Benefits Scheme, so it is a medicine dispensed under subsidy across Australia rather than one supplied through a narrower route. That is a fact about how widely it is used, not a rating of how serious this shortage is — the TGA's own impact rating above is the only severity statement on this page, and this does not change it.

A PBS listing is recorded against the active ingredient, while a shortage is usually reported against particular brands, strengths or pack sizes. So a subsidised alternative brand of the same ingredient may still be available even where a shortage is open. Your pharmacist can tell you what is in stock and can discuss substitutions with your prescriber.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Products affected

TERBINAFINE SANDOZ terbinafine (as hydrochloride) 250 mg tablet blister pack

Tablet, uncoated · ARTG 101685

Status
Current shortage The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
Supply
Limited Availability The supplier reports limited stock.
TGA impact rating
Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
Reported from
2 July 2026 The TGA's dates span 6 months.
Expected to be resolved
15 January 2027 This is the date the supplier has given the TGA. It can move.
TGA last updated
15 June 2026

What the TGA says is being done

Alternative brands are available.

Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.

TINASIL terbinafine 250mg (as hydrochloride) tablet blister pack

Tablet, uncoated · ARTG 104493

Status
Current shortage The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
Supply
Unavailable The supplier reports no stock is available.
TGA impact rating
Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
Reported from
27 August 2025 The TGA's dates span 15 months.
Expected to be resolved
30 November 2026 This is the date the supplier has given the TGA. It can move.
TGA last updated
8 May 2025

What the TGA says is being done

Alternative brands are available.

Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.

LAMISIL terbinafine 250mg (as hydrochloride) tablet blister pack

Tablet, uncoated · ARTG 43523

Status
Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
Supply
Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
TGA impact rating
Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
Reported from
1 January 2026
Expected to be resolved
The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
TGA last updated
16 June 2025

What the TGA says is being done

Alternative generic products are available.

Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.

Where this comes from

Source: Medicine Shortage Reports Database, Therapeutic Goods Administration (TGA), © Commonwealth of Australia, reproduced with permission. The TGA does not endorse Voxsanity, and nothing here is presented as a TGA view. Shortage information is free for everyone on this site, with no account and no subscription.

To read the TGA's own entry for terbinafine hydrochloride, open the TGA Medicine Shortage Reports Database and type terbinafine hydrochloride into its filter box. The TGA's register has no direct link to an individual medicine, so this is the closest link that exists. General information about medicine shortages is on the TGA's medicine shortages page.

Voxsanity last read the register on 18 August 2026.

Not medical advice. Voxsanity republishes public government health data in plain English. Speak to your pharmacist or doctor about your own medicines. Do not stop or change how you take a medicine because of anything on this page.